Kornimate/medical-research-clean huggingface dataset:
ultrasound guided femoral nerve block

Conditions: Hip Fracture

Summary: the goal of the study is to evaluate whether pain control achieved by ultrasound guided femoral nerve blockade (usfnb) is equal in efficacy to standard pain management practice of parenteral injection of opioid pain medication in patients presenting to the emergency department (ed) with hip fracture.

in this proposed protocol the investigators will conduct a prospective, randomized control trial comparing the efficacy of ultrasound guided femoral nerve blockade (usfnb) versus the standard of care pain management by parenteral injection of opioid pain medication of patients presenting with hip fracture at the bidmc ed. we hypothesize that usnfb approach will be non-inferior in achieving pain control (efficacy) and superior in the total dose of opioids (lower amount) as compared to the standard protocol. the enrolled population will be randomized 1:1 using a simple balanced randomization scheme. participants will be surveyed six times 6 times on a visual analog scale (vas)\* on their pain intensity reduction over 4 hours. physicians performing the block will be surveyed promptly following the procedure regarding difficulty performing the block and its efficacy. specific aim #1: the investigators hypothesize that in patients presenting to the ed with hip fracture, usfnb will demonstrate equal efficacy in pain relief with fewer side effects when compared to conventional parenteral opioid therapy. the investigators evaluate this hypothesis by monitoring visual analogue scales (vas) in patients receiving either usgfnb or opioid therapy over the first 4 hours of observation. the side effects will be noted during the same interval of time. specific aim #2: the investigators hypothesize that in patients presenting to the ed with hip fracture, usfnb will reduce the amount of narcotic used to control pain. the investigators will evaluate this by studying narcotic use over the first 4 hours of evaluation.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age presenting to the ed with radiographically established intra-, extracapsular hip fracture, able to consent and participate in the study and who have moderate to severe pain (numerical pain score \>= 31) at the time of enrollment. exclusion criteria: * patients with a previous history of hypersensitivity to local anesthetics, * patients who have signs of a local infection at the site of planned needle placement. * inr \> 1.4noac use within 48 hours * prophylactic low-molecular weight heparin (lmwh) within 12 hours * therapeutic lmwh within 24 hours * prophylactic unfractionated heparin (5000 units bid or tid) within 6 hours

Keywords: ultrasound bupivacaine femoral nerve block pain reduction
the effect of velaglucerase alfa (vpriv) on skeletal development in pediatric gaucher disease

Conditions: Gaucher Disease Type 1; Gaucher Disease Type 3

Summary: the purpose of this trial is to study the effect of velaglucerase alfa on skeletal bone development of children with type 1 or type 3 gaucher disease. in addition, the natural history and neurological status of children with type 3 gaucher disease will be studied.


Eligibility criteria:
inclusion criteria: * enzyme replacement therapy naive, * confirmed diagnosis of gaucher disease type 1 or 3, * able to travel to dallas, texas 1x per year for baseline plus 3 consecutive years, * able to tolerate all study procedures, * skeleton not fully formed as confirmed by dxa and mri), * and willing to receive velaglucerase alfa infusions every other week for the duration of the study. exclusion criteria: * clinically unstable, * taking or have taken bisphosphonates, * gaucher type 2, * pregnant female, * or deemed inappropriate for participation by the principal investigator.
the effect of n2o on chronic neuropathic pain patients

Conditions: Neuropathic Pain

Summary: important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block nmda receptors. nitrous oxide, an inhalant agent used extensively in anesthesia, also have antagonist property of nmda receptors. the investigators hypothesize that prolonged treatment with n2o can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.).

important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block nmda receptors. nitrous oxide, an inhalant agent used extensively in anesthesia, also have antagonist property of nmda receptors. the investigators hypothesize that prolonged treatment with n2o can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.). in order to examine our theory we will recruit 40 patients aged 18-65 that suffer from chronic neuropathic pain. the patients will be divided to two groups of which half will receive treatment with n2o and half with placebo (pure o2) as a repeated weekly treatment for 4 weeks. at the beginning of the each session the patient will be asked to fill questionnaires regarding their pain quality and severity

Eligibility criteria:
inclusion criteria: * men and women at the age 18-65 * patient that suffer from chronic neuropathic pain * vas\>40 * dn4 score \>4 * takes pain medication on a regular basis * didn't get epidural injection for the pas month * signed an informed consent form exclusion criteria: * patients that suffer from chronic lung disease. * patients with cancer * patients with heart disease * pregnant and lactate woman * patients that suffer from depression
study of the efficacy and safety of su-014813 in patients with metastatic breast cancer

Conditions: Breast Neoplasms

Summary: to determine the antitumor efficacy and the safety of su-014813 at a dose of 100 mg orally once daily in patients with metastatic breast cancer


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent. * must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. patients whose tumors are her-2-positive must have received prior trastuzumab therapy. prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease. exclusion criteria: * prior treatment with \>/= 3 regimens of chemotherapy in the metastatic disease setting beyond those containing anthracyclines and taxanes * uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic
detection of sars-cov-2 in follicular fluid and cumulus-oocyte-complexes in covid-19 patients

Conditions: Infertility; COVID; IVF

Summary: recently, the world was shaken awake by a pandemic caused by a novel coronavirus sars-cov-2 (severe acute respiratory syndrome coronavirus 2). in most nations drastic isolation measures were taken to minimize the further spread of the coronavirus disease 2019 (covid-19). being the first pandemic sparked by a coronavirus, little was known on covid-19 and its implications on general health. our understanding on the virus and its potential effects on health is growing. in belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. as also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. the limited evidence of sars-cov-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active sars-cov-2 infection on female gametes. viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out. since the onset of the pandemic, knowledge about the molecular details of sars-cov-2 infection rapidly grew. coronaviruses are enveloped rna viruses. for a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. the coronavirus surface protein spike (s) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. the sars-cov-2-s protein (sars-s) utilizes angiotensin-converting enzyme 2 (ace2) as a receptor for host cell entry. host proteases such as transmembrane serine protease 2 (tmprss2) are then needed to cleave the viral s protein, allow-ing permanent fusion of the viral and host cell membranes2. expression of ace2 and tmprss2 has been shown in testicular, uterine and placental cells. based on available transcriptomic data, co-expression of ace2 and tmprss2 is also seen on oocyte level, but the possible impact on reproduction is unknown. the bsg (basigin or cd147), a receptor on host cells, was also identified as a possible route for viral invasion.


Eligibility criteria:
inclusion criteria: * female * undergoing ivf/icsi treatment * planned for an oocyte retrieval * pcr positive of sars-cov-2 or high suspicion for covid 19 based on ct scan * signed informed consent exclusion criteria: * none
a repeated instruction by telephone on the day before colonoscopy to patients undergoing colonoscopy

Conditions: Ottawa Score; Adenoma

Summary: cell phone retell the instruction of bowel preparation on the day before colonoscopy would help patient to prepare for colonoscopy and improve the quality of the bowel preparation.

colonoscopy is the gold standard in the diagnosis of colorectal disease. the success of colonoscopy depends on high-quality bowel preparation by patients. inadequate bowel cleansing reduces the speed, the cecal intubation rate, and the number of polyps detected. it also increases costs, mostly due to repeated procedures. the quality of bowel cleansing has remained suboptimal even though numerous different products and regimens have been tested and compared in no fewer than six meta-analyses. therefore, a completely different approach to improve precolonoscopy bowel cleansing is welcome. there are many factors effect the bowel preparation such as age, cirrhosis diabetes, drug compliance, cerebral infarction, dementia, history of major surgery. 20% of patients with poor bowel preparation were due to bad compliance. studies found that addressing patient perceptions with an inexpensive and simple booklet based on the health belief model improved preparation quality. we assume that doctor retelling the instruction of bowel preparation by cell phone on the day before colonoscopy would help patient to prepare for colonoscopy and improve the quality of the bowel preparation.

Eligibility criteria:
inclusion criteria: * patients undergoing colonoscopy exclusion criteria: * disturbance of water and electrolyte * history of colorectal surgery * severe colonic stricture or obstructing tumor * known or suspected bowel obstruction or perforation * toxic colitis or megacolon * dysphagia * compromised swallowing reflex or mental status * significant gastroparesis or gastric outlet obstruction or ileus * severe chronic renal failure (creatinine clearance \<30 ml/minute) * severe congestive heart failure (new york heart association class iii or iv) * uncontrolled hypertension (average systolic blood pressure \>170 mm hg, average diastolic blood pressure \>100 mm hg) * pregnant or lactating women * patients who cannot give informed consent

Keywords: colonoscopy bowel preparation education
glutathione vs. curcumin clinical trial

Conditions: Gulf War Syndrome

Summary: the investigator proposes to perform a phase i/ii study comparing two nutraceuticals and placebo that target mediators identified in the investigator's prior dynamic modeling study of gulf war illness (gwi). the investigator will repeat the dynamic modeling before treatment and on therapy to assess the modeling and the impact of the interventions on the homeostatic networks that have identified, with an added focus on the glutathione/redox system.

in the investigator's prior study "dynamic modeling in gwi", the investigator used an exercise stress model (rest, peak oxygen consumption oxygen uptake, and 7 follow-up sampling points) to measure the mediators of relapse in the context of their interactive homeostatic networks. the investigator surveyed the response of genes and blood-borne biomarkers in order to interrogate and map regulation of neuro-endocrine-autonomic-immune function in these subjects as compared to gw era sedentary healthy controls. the investigator's research team applied an integrative systems-based approach rooted in computational biology connecting gene expression and biomarkers to pathways and to symptoms in order to identify potential therapeutic targets as well as optimal strategies for manipulation of these targets. using this data the investigator's research team has developed a virtual model of the illness, which has been used to identify potential therapeutic targets.

Eligibility criteria:
inclusion criteria: * veterans with gulf war illness * 35 to 70 years old * good health by medical history prior to 1990 * currently have no exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity exclusion criteria: * major depression with psychotic or melancholic features * schizophrenia * bipolar disorder * delusional disorders * dementias of any type * history or current alcohol abuse * history or current drug abuse * current tobacco use * organ failure * defined rheumatologic * inflammatory disorders * hiv * hepatitis b and c * primary sleep disorders * steroids * immunosuppressives
" application of art therapy in oncology: evaluation of the symptomatic of patients suffering from a cancerous disease"

Conditions: Therapy-Associated Cancer

Summary: the purpose of this study is to evaluate the impact of art-therapeutic management on a patient with cancer, during chemotherapy treatment, on the reduction of physical or psychological symptoms. art therapy is a non-drug approach that can help some patients cope with the consequences of cancer beyond the care provided. the common psychosocial difficulties experienced by cancer patients are pain, fatigue, depression, anxiety, drowsiness. in sum, the well-being and quality of life of the patient throughout the illness. the main objective is to evaluate the impact of art therapy, as a supportive care, on improving the well-being felt after a session of cancer treatments (chemotherapy, immunotherapy, ...), during 6 sessions( around 24 days between 2 sessions) , at patients with a cancer pathology using two questionnaires, one on the evaluation of symptoms (esas), the other on the quality of life (fact-g).

patients will be randomized into the following groups: * group 1: art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care * group 2: 6 consecutive sessions of cancer treatments with or without additional supportive care. symptom assessment with the edmonton symptom assessment system (esas) is done before and after each treatment session for each patient. the fact-g questionnaire on the quality of life at the beginning and the end of the care for the two groups (group benefiting from the art-therapy and group not benefiting from the art-therapy) and a questionnaire on the contribution of art therapy, at the end of care, for the participants of the art-therapy group.

Eligibility criteria:
inclusion criteria: * aged over 18 * patient cared for on onco-hematology day with a cancerous pathology * consent of the patient * patient affiliated to social security exclusion criteria: * patient minor * patient under legal protection * patient with too much impairment of vital and / or cognitive functions to participate and understand the study * patient whose predictable management is less than the follow-up period (6 sessions), * patient who has already participated in an art therapy session during their lifetime

Keywords: oncology art therapy
a study of xl844 administered as a single agent and in combination with gemcitabine in adults with advanced malignancies

Conditions: Cancer; Lymphoma

Summary: the purpose of this study is to determine a safe dose of xl844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and xl844.


Eligibility criteria:
inclusion criteria: 1. the subject has a histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival. 2. the subject has disease that is assessable by tumor marker, physical, or radiologic means. 3. the subject is ≥18 years old. 4. the subject has an ecog (eastern cooperative oncology group) performance status of ≤2. 5. the subject has adequate organ and marrow function. 6. the subject has the capability of understanding the informed consent document and has signed the informed consent document. 7. sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study. 8. female subjects of childbearing potential must have a negative pregnancy test at screening. 9. if a subject has received more than three prior regimens of cytotoxic chemotherapy, more than two biologic regimens, or more than 3000 cgy to \>25% of his or her bone marrow, the investigator must discuss with the sponsor regarding subject suitability before enrollment. 10. the subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥5 years ago, and has had no evidence of disease for 5 years prior to screening for this study). exclusion criteria: 1. the subject has received anticancer treatment (eg, chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agent, or hormones) within 14 days prior to the first dose of study drug. 2. the subject has not recovered to grade ≤1 from adverse events (aes) due to investigational agents or other medications administered more than 30 days prior to the first dose of study drug. 3. the subject has received radiation to \>25% of his or her bone marrow within 30 days of xl844 treatment. 4. the subject has a primary brain tumor or known brain metastases. 5. the subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 6. the subject is pregnant or breastfeeding. 7. the subject is known to be positive for the human immunodeficiency virus (hiv). 8. the subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee. 9. the subject has a known allergy or hypersensitivity to any of the components of the xl844 formulation or gemcitabine.

Keywords: advanced malignancies solid tumor
study assessing utility of a clinical questionnaire to identify subjects with features of both asthma and chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of the study is to identify demographic and non-spirometric clinical features predictive of the asthma-copd overlap population. the study aims to explore and identify characteristics of the asthma-copd overlap syndrome (acos) patient's clinical profile that enable clinical differentiation from subjects with a primary diagnosis of either asthma alone (without persistent obstruction) or copd alone (without reversibility). the study is designed as a targeted medical history survey which consists of a 41-item questionnaire, which will be administered by a qualified health care practitioner at the time a subject's medical history is taken. the questionnaire has been developed to elicit specific details of the respiratory history, including the following: bronchodilator use, disease progression, variation in symptoms, atopic history, symptom triggers, vagal bias, burden of disease, symptom presentation, co morbidities and age of onset. in addition, demographic information, standard medical history, co morbidity and spirometric results will also be obtained and analyzed in conjunction with the questionnaire results. approximately 1000 subjects are required for the study.


Eligibility criteria:
inclusion criteria: * subject must be 18 years of age or older. * subject has been diagnosed as having asthma and/or copd. * informed consent is required for independent sites initiating this protocol

Keywords: asthma asthma-copd overlap syndrome clinical questionnaire copd acos
comparison of ultrasound, ct, and classical methods for selecting sizes and placement of left-sided double-lumen tubes

Conditions: Thoracic Neoplasms

Summary: investigators aimed to compare anatomical measurements obtained using ultrasound and computed tomography with classical methods to select the appropriate size of double-lumen tubes more quickly and easily and to determine the optimal depth of placement.

in modern thoracic anesthesia, one-lung ventilation (olv) is essential for managing surgeries, and double-lumen tubes (dlts) have been a key advancement. dlts allow separate lung ventilation, facilitating lung deflation and preventing material transfer to the healthy lung. however, improper dlt placement can compromise these functions, emphasizing the importance of correct sizing and positioning. choosing the right dlt size depends heavily on patient-specific factors. undersized dlts can cause airway injuries, increased resistance, and displacement, while oversized dlts are linked to postoperative issues like sore throat and difficult intubation. despite this, no universal criterion exists for dlt size selection. traditional methods rely on height and gender, but weak correlations with airway size often lead to improper choices, especially in shorter individuals. imaging techniques like chest x-rays, computed tomography (ct), and ultrasonography (usg) offer a more precise approach to airway measurements for dlt selection. usg is especially advantageous due to its accessibility, speed, and ease of use in operating rooms and emergencies. to improve the accuracy and ease of dlt size selection and placement, investigators aimed to compare anatomical measurements from usg and ct with traditional methods.

Eligibility criteria:
inclusion criteria: * requiring lung isolation in thoracic surgery, * american society of anesthesiologists (asa) risk score of 1-2-3, * patients who are literate and able to provide informed consent exclusion criteria: * patients with an asa score of 4 or higher, * criteria for difficult intubation, * difficulty in mouth opening, small jaw deformities, * abnormal cricoid cartilage appearance, * a history of laryngeal or neck surgery, * preoperative throat pain and hoarseness, * tumors and deformities in the main airway

Keywords: double lumen tube size depth malposition ultrasonography computed tomography fiber optic bronchoscopy